Skip to main content
. 2023 Sep 20;11:1122408. doi: 10.3389/fcell.2023.1122408

FIGURE 6.

FIGURE 6

Activity of MMP2 and MMP9 in cardiac fibroblasts and CF-neutrophils co-cultures. (A) CF were pre-stimulated with ruxolitinib for 30 min before IFN-β treatment. CF were pre-stimulated with IFN-beta (500 IU/mL) for 1 h and subsequently stimulated with LPS (1 μg/ml) for 24 h. In treated CF alone and in pre-treated CF co-cultured with the MMPs activity was measured as indicated in materials and methods. A representative image of the experiment is shown in the upper panel and its quantification appears in the lower panel. (A) MMP2 activity in CF alone (white bars) and in a CF-Neutrophils co-culture (black bars). *p < 0.05; **p < 0.01 vs. non-treated CF; #p < 0.05 Ruxolitinib + IFN-β vs. Ruxolitinib + IFN-β + LPS; ##p < 0.01 IFN-β vs. Ruxolitinib + IFN-β; &p < 0.05 CF vs. CF + neutrophils. (B) MMP9 activity in CF alone (white bars) and in a co-culture of CF-Neutrophils (black bars).). *p < 0.05; ***p < 0.001 CF vs. treated CF-neutrophils; #p < 0.05 no treated CF vs. IFN-β and Ruxolitinib + IFN-β. Results are expressed as mean ± SEM. (n = 3).